Furthermore, in several breast cancer cell lines, RGZ activated the human Fas ligand (FasL) promoter in a PPARγ-dependent manner, increased the binding of PPARγ with Sp1 to the Sp1 sequence located within the FasL promoter, and positively regulated FasL expression [188]. Here, FASLG is linked to breast carcinoma.